CYP2C18

Across TCGA pan-cancer cohorts, CYP2C18 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP2C18 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CYP2C18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYP2C18 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

LIHC, COAD, and BLCA are the cancer types where CYP2C18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.784	<.001	18	view →
COAD	OS	Median	II,III,IV	0.267	0.787	.002	15	view →
BLCA	DFS	Median	II,III,IV	1.000	0.607	.025	6	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.841	0.665	.005	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP2C18–LIHC (OS)

Open the LIHC breakdown →